Table of Contents Table of Contents
Previous Page  351 476 Next Page
Information
Show Menu
Previous Page 351 476 Next Page
Page Background

Pettersson, David Robinson, Mats Ande´n, Jan-Erik Damber, Jonas

Hugosson, Maria Nyberg, Go¨ran Ahlgren, Ola Bratt, Rene´ Blom, Lars

Egevad, Calle Waller, Olof Akre, Per Fransson, Eva Johansson, Fredrik

Sandin, Hans Garmo, Mats Lambe, Karin Hellstro¨m, Annette Wigertz, and

Erik Holmberg.

[3_TD$DIFF]

During the time of this research, Prasanna Sooriakumaran

[4_TD$DIFF]

was part-funded by the National Institute for Health Research Oxford

Biomedical Research Centre based at Oxford University Hospitals NHS

Trust and the University of Oxford, but not directly for the submitted

work. Olof Akre is supported by a grant from the Swedish Cancer Society,

again not directly for the submitted work. PeterWiklund is supported by a

grant from the Swedish Research Council K2013-99X-22283-01-3, again

not directly for the submitted work. Prasanna Sooriakumaran and Peter

Wiklund had full access to all the data in the study and take responsibility

for the integrity of the data and the accuracy of the data analysis.

Appendix A. Supplementary data

Supplementary material related to this article can be

found, in the online version, at

http://dx.doi.org/10.1016/j. eururo.2017.04.002

.

References

[1]

Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.

[2]

Yossepowitch O, Bianco Jr FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007;51:940–7, dis- cussion 7–8.

[3]

Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 2014;65:124–37.

[4]

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–59

.

[5]

Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–70.

[6]

Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy fol- lowed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–9

.

[7]

Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor?. A SEER-based study. Eur Urol 2014;65: 1058–66

.

[8]

Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register- based resource for prostate cancer research. Scand J Urol Nephrol 2009;43:342–9

.

[9]

Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2013;42:956–67.

[10]

Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011;185:833–9.

[11]

Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 2014;348, g1502

.

[12]

Fine JP, Gray RJ. A proportional hazards model for the subdistribu- tion of a competing risk. J Am Stat Assoc 1999;94:496–509

.

[13]

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011;8:CD007565.

[14]

Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from diges- tive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219–28

.

[15]

Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004;22:3475–84.

[16]

Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009;27:1549–56.

[17]

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559–64

.

[18]

Morgan TM, Lange PH, Porter MP, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009;15:677–83

.

[19]

Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic dis- ease. J Urol 2002;168:1008–12.

[20]

Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long- term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-depriva- tion therapy. Eur Urol 2014;65:20–5

.

[21]

Gakis G, Boorjian SA, Briganti A, et al. The role of radical prostatec- tomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 2014;66:191–9

.

[22]

Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014;66:602–3.

[23]

Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352–7.

[24]

Rider JR, Sandin F, Andren O, Wiklund P, Hugosson J, Stattin P. Long- term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013;63:88–96.

[25]

Won AC, Gurney H, Marx G, De Souza P, Patel MI. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 2013;112:E250–5

.

[26]

Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol 2006;176:1292–8.

[27]

Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016;69:788–94.

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 4 5 – 3 5 1

351